Active-specific immunization against melanoma: Is the problem at the receiving end?

Vladia Monsurrò, Ena Wang, Monica C. Panelli, Dirk Nagorsen, Ping Jin, Zavaglia Katia, Kina Smith, Yvonne Ngalame, Jos Even, Francesco M. Marincola

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

The recent progress in tumor immunology is a striking example of the successful application of modern biotechnology to understand the complex phenomenon of immune-mediated cancer rejection. Tumor antigens were identified and successfully utilized in active immunization trials to induce tumor antigen-specific T cells. This achievement has left, however, clinicians and researchers perplexed by the paradoxical observation that immunization-induced T cells can recognize tumor cells in standard assays but cannot induce tumor regression. A closer look at T cell physiology and tumor biology suggests that this observation is not so surprising. Here, we argue that successful immunization is one of several steps required for tumor clearance while more needs to be understood about how T cells localize and are effective within a tumor microenvironment impervious to the execution of their effector function.

Original languageEnglish
Pages (from-to)473-480
Number of pages8
JournalSeminars in Cancer Biology
Volume13
Issue number6
DOIs
Publication statusPublished - 2003
Externally publishedYes

Fingerprint

Melanoma
Vaccination
T-Lymphocytes
Neoplasms
Neoplasm Antigens
Immunization
Cell Physiological Phenomena
Tumor Microenvironment
Biotechnology
Allergy and Immunology
Antigen-Antibody Complex
Research Personnel

Keywords

  • Immunization
  • Immunotherapy
  • Interleukin-2
  • Melanoma

ASJC Scopus subject areas

  • Cancer Research

Cite this

Monsurrò, V., Wang, E., Panelli, M. C., Nagorsen, D., Jin, P., Katia, Z., ... Marincola, F. M. (2003). Active-specific immunization against melanoma: Is the problem at the receiving end? Seminars in Cancer Biology, 13(6), 473-480. https://doi.org/10.1016/j.semcancer.2003.09.011

Active-specific immunization against melanoma : Is the problem at the receiving end? / Monsurrò, Vladia; Wang, Ena; Panelli, Monica C.; Nagorsen, Dirk; Jin, Ping; Katia, Zavaglia; Smith, Kina; Ngalame, Yvonne; Even, Jos; Marincola, Francesco M.

In: Seminars in Cancer Biology, Vol. 13, No. 6, 2003, p. 473-480.

Research output: Contribution to journalArticle

Monsurrò, V, Wang, E, Panelli, MC, Nagorsen, D, Jin, P, Katia, Z, Smith, K, Ngalame, Y, Even, J & Marincola, FM 2003, 'Active-specific immunization against melanoma: Is the problem at the receiving end?', Seminars in Cancer Biology, vol. 13, no. 6, pp. 473-480. https://doi.org/10.1016/j.semcancer.2003.09.011
Monsurrò, Vladia ; Wang, Ena ; Panelli, Monica C. ; Nagorsen, Dirk ; Jin, Ping ; Katia, Zavaglia ; Smith, Kina ; Ngalame, Yvonne ; Even, Jos ; Marincola, Francesco M. / Active-specific immunization against melanoma : Is the problem at the receiving end?. In: Seminars in Cancer Biology. 2003 ; Vol. 13, No. 6. pp. 473-480.
@article{3e01d675cc2c4d9d9ad7376933a41cde,
title = "Active-specific immunization against melanoma: Is the problem at the receiving end?",
abstract = "The recent progress in tumor immunology is a striking example of the successful application of modern biotechnology to understand the complex phenomenon of immune-mediated cancer rejection. Tumor antigens were identified and successfully utilized in active immunization trials to induce tumor antigen-specific T cells. This achievement has left, however, clinicians and researchers perplexed by the paradoxical observation that immunization-induced T cells can recognize tumor cells in standard assays but cannot induce tumor regression. A closer look at T cell physiology and tumor biology suggests that this observation is not so surprising. Here, we argue that successful immunization is one of several steps required for tumor clearance while more needs to be understood about how T cells localize and are effective within a tumor microenvironment impervious to the execution of their effector function.",
keywords = "Immunization, Immunotherapy, Interleukin-2, Melanoma",
author = "Vladia Monsurr{\`o} and Ena Wang and Panelli, {Monica C.} and Dirk Nagorsen and Ping Jin and Zavaglia Katia and Kina Smith and Yvonne Ngalame and Jos Even and Marincola, {Francesco M.}",
year = "2003",
doi = "10.1016/j.semcancer.2003.09.011",
language = "English",
volume = "13",
pages = "473--480",
journal = "Seminars in Cancer Biology",
issn = "1044-579X",
publisher = "Academic Press Inc.",
number = "6",

}

TY - JOUR

T1 - Active-specific immunization against melanoma

T2 - Is the problem at the receiving end?

AU - Monsurrò, Vladia

AU - Wang, Ena

AU - Panelli, Monica C.

AU - Nagorsen, Dirk

AU - Jin, Ping

AU - Katia, Zavaglia

AU - Smith, Kina

AU - Ngalame, Yvonne

AU - Even, Jos

AU - Marincola, Francesco M.

PY - 2003

Y1 - 2003

N2 - The recent progress in tumor immunology is a striking example of the successful application of modern biotechnology to understand the complex phenomenon of immune-mediated cancer rejection. Tumor antigens were identified and successfully utilized in active immunization trials to induce tumor antigen-specific T cells. This achievement has left, however, clinicians and researchers perplexed by the paradoxical observation that immunization-induced T cells can recognize tumor cells in standard assays but cannot induce tumor regression. A closer look at T cell physiology and tumor biology suggests that this observation is not so surprising. Here, we argue that successful immunization is one of several steps required for tumor clearance while more needs to be understood about how T cells localize and are effective within a tumor microenvironment impervious to the execution of their effector function.

AB - The recent progress in tumor immunology is a striking example of the successful application of modern biotechnology to understand the complex phenomenon of immune-mediated cancer rejection. Tumor antigens were identified and successfully utilized in active immunization trials to induce tumor antigen-specific T cells. This achievement has left, however, clinicians and researchers perplexed by the paradoxical observation that immunization-induced T cells can recognize tumor cells in standard assays but cannot induce tumor regression. A closer look at T cell physiology and tumor biology suggests that this observation is not so surprising. Here, we argue that successful immunization is one of several steps required for tumor clearance while more needs to be understood about how T cells localize and are effective within a tumor microenvironment impervious to the execution of their effector function.

KW - Immunization

KW - Immunotherapy

KW - Interleukin-2

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=10744224733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744224733&partnerID=8YFLogxK

U2 - 10.1016/j.semcancer.2003.09.011

DO - 10.1016/j.semcancer.2003.09.011

M3 - Article

C2 - 15001166

AN - SCOPUS:10744224733

VL - 13

SP - 473

EP - 480

JO - Seminars in Cancer Biology

JF - Seminars in Cancer Biology

SN - 1044-579X

IS - 6

ER -